The makings of a tumor rejection antigen (Q33748013)

29 July 2017

1 reference

title

The makings of a tumor rejection antigen (English)

1 reference

29 July 2017

Gilboa E

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

263-270

1 reference

Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Human tumor antigens recognized by T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Analysis of a successful immune response against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Antitumor immunity at work in a melanoma patient

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Oncogenic proteins as tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

CD4+ T cells orchestrate both amplification and deletion of CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Immunotherapy of cancer with dendritic-cell-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Advances in cancer vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Immune surveillance against a solid tumor fails because of immunological ignorance

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Escape of thymocytes and mature T cells from clonal deletion due to limiting tolerogen expression levels

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Tolerance is overcome in beef insulin-transgenic mice by activation of low-affinity autoreactive T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

B cells inhibit induction of T cell-dependent tumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

CTL Response and Protection Against P815 Tumor Challenge in Mice Immunized with DNA Expressing the Tumor-Specific Antigen P815A

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Serological identification of human tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

The emerging role of CTLA-4 as an immune attenuator

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

CD4 T cells and their role in antitumor immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Antigen recognition by class I-restricted T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Role of Fas-mediated cell death in the regulation of immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980101-6

7 January 2021

10.1016/S1074-7613(00)80101-6

Identifiers

DOI

1 reference

29 July 2017

1 reference